Evidence map›Paper›PMID 34020208›Full record

Observational studyJournal of infection and public health2021

Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean.

Mara García-Posada, Sandra Aruachan-Vesga, Danis Mestra, Katherine Humánez, Héctor Serrano-Coll, Heriberto Cabrales, Álvaro Faccini, Salim Mattar

Open access · goldAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of infection and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 5 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Mara García-PosadaInfectology and Epidemiology Service, IMAT-Oncomédica, Montería, Colombia.
Sandra Aruachan-VesgaClinical Research Department, IMAT-Oncomédica, Montería, Colombia.
Danis MestraClinical Research Department, IMAT-Oncomédica, Montería, Colombia.
Katherine HumánezClinical Research Department, IMAT-Oncomédica, Montería, Colombia.
Héctor Serrano-CollTropic Biological Research Institute, Universidad de Córdoba, Montería, Colombia.
Heriberto CabralesInternal Medicine Service, IMAT-Oncomédica, Montería, Colombia.
Álvaro FacciniTropic Biological Research Institute, Universidad de Córdoba, Montería, Colombia.
Salim MattarTropic Biological Research Institute, Universidad de Córdoba, Montería, Colombia. Electronic address: mattarsalim@hotmail.com.
University of Córdoba · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDespite the high volume of infections, some clinical aspects of this disease are still unknown. There are currently no studies in Colombia that describe the disease's clinical and treatment aspects in detail.

objectiveDescribe the characteristics and clinical management of a group of admitted patients with SARS-CoV-2 infection in a private clinic in Montería, Córdoba-Colombia. PATIENTS AND

methodsA descriptive observational study was carried out between May and August 2020 in 209 hospitalized patients with a confirmed diagnosis of COVID-19. Upon admittance, clinical, sociodemographic characteristics, comorbidities, and complications were analyzed. Additionally, the effect of the following medications was described: 1-antibiotics (cefepime, piperacillin, tazobactam, meropenem, vancomycin) + low molecular weight heparin (LMWH) + corticosteroids (dexamethasone-methylprednisolone) + colchicine. 2- Antibiotic + LMWH + corticosteroids. 3-LMWH + corticosteroids. 4-LMWH + corticosteroids + colchicine. 5-Other treatments (Tocilizumab).

results107 (51%) of the 209 patients with a confirmed diagnosis of COVID-19 passed away. The main comorbidities related to mortality of these hospitalized patients with COVID-19 were obesity and kidney disease (P < 0.05). The main complications associated with fatal outcomes in this group of patients were Acute Respiratory Distress Syndrome (ARDS) and sepsis (P < 0.05). Furthermore, it was evidenced that the colchicine combination showed a significant difference in reducing mortality in hospitalized patients compared to the other therapeutic regimens (P < 0.05).

conclusionA mortality rate of 51% was found attributable to several factors such as advanced age, obesity, kidney disease, and an average time in days of late consultation. The implementation of the colchicine combination could reduce the mortality rate in this disease.

Indexed as

COVID-19Caribbean RegionColombiaHeparin, Low-Molecular-WeightHumansSARS-CoV-2Heparin, Low-Molecular-WeightColchicineCOVID-19 drug treatmentEmerging infectious diseaseMortality determinantPublic health surveillanceTherapeutics

Identifiers

PMID34020208
PMCPMC8101281
OpenAlexW3134723238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.